Clinical Trials
7 trialsNCT04284774 2026-05-27
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03155620 2026-05-05
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02535650 2022-03-08
Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma
Samsung Medical Center
Phase 2 Unknown
NCT00047216 2015-07-23
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
University Health Network, Toronto
Phase 2 Completed
NCT00006376 2013-12-04
R115777 in Treating Patients With Advanced Bladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005848 2013-07-11
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Fox Chase Cancer Center
Phase 2 Completed
NCT00005842 2013-02-11
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed